The Effect of Upadacitinib on Lipid Profile and Cardiovascular Events: A Meta-Analysis of Randomized Controlled Trials.
Anastasios MakrisHaralampos MilionisPetros P SfikakisEvangelos N LiberopoulosAris P AgouridisPublished in: Journal of clinical medicine (2022)
Treatment with upadacitinib increases both LDL-C and HDL-C levels. Nevertheless, upadacitinib had no significant effect on the cardiovascular disease risk during a ≤52-week follow-up.